| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5537595 | Vaccine | 2017 | 10 Pages |
Abstract
H1:IC31 was safe and immunogenic in uninfected and M.tb-infected adolescents. Two administrations of the 15 μg H1:IC31 dose induced the greatest magnitude immune response, and was considered optimal (South African National Clinical Trials Register, DoH-27-0612-3947; Pan African Clinical Trial Registry, PACTR201403000464306).
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Helen Mearns, Hennie D. Geldenhuys, Benjamin M. Kagina, Munyaradzi Musvosvi, Francesca Little, Frances Ratangee, Hassan Mahomed, Willem A. Hanekom, Søren T. Hoff, Morten Ruhwald, Ingrid Kromann, Peter Bang, Mark Hatherill, Peter Andersen,